News Collegium Pharmaceutical, Inc.

Stocks

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-29 EDT			5-day change	1st Jan Change
24.03 ^USD	+3.44%		+4.87%	-48.10%

10-19	Collegium Pharmaceutical Settles Nucynta Patent Litigation for $17 Million	MT
10-09	Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says	MT

All News

Mentions Relevance

08:00am	Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts	GL
10-22	Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026	GL
10-21	Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses	GL
10-19	Collegium Pharmaceutical Settles Nucynta Patent Litigation for $17 Million	MT
10-09	Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says	MT
10-06	Collegium Pharmaceutical, Inc. Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life	CI
10-06	Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life	GL
09-23	Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says	MT
09-23	Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target	MT
09-15	Collegium Pharmaceutical, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 04:05 PM
09-09	Leerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price Target	MT
09-09	Truist Cuts Price Target on Collegium Pharmaceutical to $49 From $58, Keeps Buy Rating	MT
09-08	Collegium to Participate in Upcoming Investor Conferences	GL
08-13	Collegium Pharmaceutical Enters $50 Million Accelerated Share Repurchase Agreement	MT
08-13	Collegium Announces $50 Million Accelerated Share Repurchase Program	GL
08-06	Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Year 2026	CI
08-06	Collegium Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Collegium Pharmaceutical, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06	(COLL) Collegium Pharmaceutical Expects 2026 Net Product Revenue Range $825M to $855M	MT
08-06	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Reports Q2 Revenue $199.9M, vs. FactSet Est of $199.6M	MT
08-06	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Posts Q2 Adjusted EPS $1.92 per Share, vs. FactSet Est of $1.72	MT
08-06	Collegium Pharmaceutical: Q2 Earnings Snapshot	AQ
08-06	Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on July 7, 2025.	CI
08-06	Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress	GL
08-06	Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress	AQ